` BIOG B (Biogaia AB) vs OMX Stockholm 30 Comparison - Alpha Spread

BIOG B
vs
OMX Stockholm 30

Over the past 12 months, BIOG B has underperformed OMX Stockholm 30, delivering a return of -12% compared to the OMX Stockholm 30's 5% drop.

Stocks Performance
BIOG B vs OMX Stockholm 30

Loading

Performance Gap
BIOG B vs OMX Stockholm 30

Loading
BIOG B
OMX Stockholm 30
Difference

Performance By Year
BIOG B vs OMX Stockholm 30

Loading
BIOG B
OMX Stockholm 30
Add Stock

Competitors Performance
Biogaia AB vs Peers

OMX Stockholm 30
BIOG B
ABBV
AMGN
GILD
VRTX
Add Stock

Biogaia AB
Glance View

Market Cap
10.2B SEK
Industry
Biotechnology

BioGaia AB engages in the development, marketing, and sale of probiotic products. The company is headquartered in Stockholm, Stockholm. The firm develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The firm operates worldwide.

BIOG B Intrinsic Value
121.45 SEK
Undervaluation 17%
Intrinsic Value
Price
Back to Top